New drug cocktail shows promise for tough lung cancer cases
NCT ID NCT00238628
First seen Jun 08, 2026 · Last updated Jun 16, 2026 · Updated 4 times
Summary
This early-phase study tested a combination of two drugs, bexarotene and Iressa, in 6 people with advanced non-small cell lung cancer who had already tried other treatments. The goal was to see if the combination was safe and could help control the disease. The study looked at how long patients lived and how long the cancer stayed stable.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Stanford University School of Medicine
Stanford, California, 94305, United States
Conditions
Explore the condition pages connected to this study.
Conditions inferred from the trial description
These were inferred from the trial's summary, not listed by the trial registrant.